Malignant mesothelioma is among the rarest forms of cancer. It is also one of the most difficult to treat. Mesothelioma continues to be considered a fatal diagnosis, despite strides that have been made in improving longevity for many of those identified as having the disease. It is the challenge of treating the condition, as well
CAR T-cell therapy is a new type of immunotherapy for cancer treatment that might benefit mesothelioma patients. Clinical trials represent a unique opportunity for patients who qualify to access innovative medicine with great promise. CAR T-cell therapy modifies a patient’s immune system cells and has already shown good results with bone marrow and blood cancers.
The fiberglass connection to mesothelioma is a concern because it has replaced asbestos in most insulation. While not nearly as dangerous to human health, glass fibers can still cause harm. Insulators working today might also come in contact with old asbestos insulation, which can lead to mesothelioma. What Is Fiberglass? Fiberglass is a synthetic mineral
Atezolizumab (Tecentriq) is an immunotherapy drug currently under study in clinical trials to treat mesothelioma. It is already used to treat bladder, breast, and lung cancers. If you are interested in getting involved in a trial with atezolizumab, talk to your specialists to determine if you qualify for clinical trials. What Is Atezolizumab? Atezolizumab is
Mesothelioma durvalumab clinical trials are testing the safety and effectiveness of this immunotherapy drug for pleural mesothelioma patients. This is also a targeted therapy that may only work for cancers that express a specific protein. The FDA has approved durvalumab to treat bladder cancer and non-small cell lung cancer. What Is Durvalumab? Durvalumab is made
Opdivo (nivolumab) and Yervoy (ipilimumab) are immunotherapy drugs approved to treat pleural mesothelioma. The National Comprehensive Cancer Network (NCCN) recommends that physicians use a combination of both agents for treating mesothelioma that has progressed through an initial first-line treatment. What Is Nivolumab and Ipilimumab Combination Mesothelioma Treatment? In 2020, the U.S. Food and Drug Administration
VISTA protein clinical trials recently tested a drug known as CA-170 for its potential effectiveness as a type of cancer therapy. CA-170 is an immunotherapy drug that prevents the deactivation of immune system T-cells by cancer cells. The trials, which included mesothelioma patients, recently concluded. What Is VISTA? Immune Checkpoint Proteins and Inhibitors VISTA (V-domain
Mesothelioma is an equal opportunity disease. It impacts everybody who has been exposed to asbestos, regardless of age, gender, or other demographic information. However, not everybody is equally at risk for exposure to asbestos. It has long been known that there are certain occupations that historically had a higher degree of exposure to the carcinogenic
Once a victim of asbestos exposure is diagnosed with mesothelioma, they have numerous decisions to make, and one of the most important for their family is whether or not to pursue legal action against the company that exposed them to the carcinogenic material. Filing a mesothelioma lawsuit can lead to significant compensation that both pays
Biotech company Curis, Inc., a leader in innovative cancer treatments, has announced that as part of a Phase I clinical trial of their new drug CA-170, they’ve enrolled and dosed their first mesothelioma patient. The oral medication targets cancer cells that express high levels of VISTA, a protein understood to help cancer cells resist treatment.